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Abstract 
Nanoparticulate imaging probes have become an increasingly important arsenal in the visu-
alization of molecular markers for early diagnosis and post-therapy assessment of diseases. 
Surface functionalization of these nanoparticles has led to the development of a variety of 
targeted nanoprobes for various imaging modalities (e.g. PET, MRI, optical). Despite these 
advances, detailed understanding of the nanoparticle targeting kinetics, particularly at the early 
time points immediately after injection, is still lacking. In this study, we report the combination 
of a T2*-weighted time-resolved-MRI (TR-MRI) method with ultra-sensitive superparamag-
netic  polymeric  micelle  (SPPM)  nanoprobes  to  quantify  the  targeting  kinetics  of  cyclic 
(RGDfK) (cRGD)-encoded SPPM to angiogenic endothelium in subcutaneous human tumor 
xenograft models in mice. TR-MRI analyses of the αvβ3-targeted and non-targeted SPPMs 
allowed for the subtraction of blood volume and extravascular signal components from the 
cRGD-SPPM data, resulting in a specific measurement of the accumulation kinetics of nano-
probes in lung, breast and brain cancer preclinical models. In all three models, αvβ3-specific 
accumulation of SPPM nanoprobes was observed in the first 5 mins after intravenous injection 
(first order rate constants were in the range of 0.22-0.24 min
-1). Similar αvβ3-targeting kinetics 
was observed for cRGD-SPPM nanoprobes in different tumor xenograft models, consistent 
with the targeting of mouse angiogenic endothelium despite tumor inoculation from different 
human cancer cell lines. Results from this study offer new opportunities in the quantitative 
characterization of the targeting kinetics of cancer-specific nanoparticles to their intended 
biological targets in an intact animal, which provides fundamental insights on molecular 
recognition processes in vivo for further development of these nanoprobes. 
Key words: Cancer molecular imaging, αvβ3, time-resolved magnetic resonance imaging, nanopar-
ticle targeting kinetics 
INTRODUCTION 
Nanosized imaging probes (e.g. quantum dots, 
iron  oxide  nanoparticles,  radiolabeled  dendrimers) 
have greatly impacted the field of molecular and cel-
lular imaging for the early diagnosis and assessment 
of therapeutic efficacy in a variety of diseases [1-4]. 
Among many clinical imaging  modalities (e.g. PET, Theranostics 2011, 1 
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SPECT,  ultrasound),  recent  advances  of  ul-
tra-sensitive nanoprobes have greatly broadened the 
capability  of  magnetic  resonance  imaging  (MRI)  in 
cancer molecular imaging applications. Compared to 
low-molecular weight T1 contrast agents, superpara-
magnetic  iron  oxide  nanoparticles  (i.e.  Fe3O4, 
MnFe2O4,  FeCo)  have  substantially  larger  molar  re-
laxivities  with  detection  limits  in  the  nanomolar  to 
picomolar  concentration  range  [5-10].  Imaging  of 
various cancer-specific biomarkers, such as αvβ3 and 
αvβ5  integrins,  Her2-neu,  transferrin  and  folate  re-
ceptors have been reported [9, 11-17]. In most of these 
applications,  pre-contrast  images  are  first  obtained, 
which is followed by injection of targeted nanoprobes 
and  after  certain  time  (typically  several  hours), 
post-contrast  images  are  acquired  by  conventional 
T2/T2*-weighted  methods  to  evaluate  the  accumula-
tion  of  nanoprobes  in  the  targeted  tissues.  Despite 
many  successful  reports  on  such  contrast  changes 
between  pre-  and  post-injection  images,  very  few 
studies have examined the fundamental kinetic pro-
cesses of molecular targeting of cancer biomarkers in 
vivo. Characterization of the early binding events and 
uptake of the nanoprobes in targeted cancer cells will 
provide important information on the critical factors 
that  affect  nanoparticle  accumulation  and  tu-
mor/normal tissue contrast in vivo. This knowledge 
will be particularly important for the development of 
vascular-targeted contrast agents, where nanoprobes 
can directly bind to the cell surface receptors of the 
tumor endothelium.  
Dynamic contrast enhanced (DCE) MRI has been 
clinically used in cancer detection, diagnosis, stratifi-
cation and assessment of anti-angiogenic therapy [18]. 
By acquiring T1-weighted images at a temporal reso-
lution  of  seconds  during  the  administration  of 
non-specific, low-molecular weight T1 contrast agents 
(e.g. Gd-DTPA), DCE-MRI allows for measurements 
of  pharmacokinetic  parameters  which  represent  the 
volume  transfer  constant  (Ktrans,  a  combination  of 
vascular flow, vessel surface area and permeability), 
the fractional volume of the extravascular extracellu-
lar space (ve) and other transport parameters in be-
nign and malignant tumor tissues [19, 20]. Although 
Gd-based small molecular agents work well in tumor 
perfusion studies, these agents are not very sensitive, 
requiring  millimolar  (10-3  M)  concentrations  for  de-
tection, and therefore are ineffective for the specific 
visualization  of  protein  biomarkers  for  molecular 
imaging in vivo [21].  
In  this  study,  we  describe  the  use  of 
T2*-weighted  time-resolved  (TR)-MRI  method  with 
1.3 s temporal resolution over 30 mins to investigate 
the  early  phase  of  the  targeting  kinetics  of  an 
αvβ3-specific  superparamagnetic  nanoprobes  in  dif-
ferent tumor xenografts in athymic  nude mice. The 
nanoprobe design is based on the superparamagnetic 
polymeric micelles (SPPM) that have been previously 
established in our lab as αvβ3 integrin-specific molec-
ular  imaging  probes  [9,  22].  Micelle  nanoparticles 
have several unique advantages in their application as 
targeted  MRI  nanoprobes.  Their  core-shell  architec-
ture allows for the loading of a cluster of superpara-
magnetic  iron  oxide  (SPIO)  nanoparticles  that  were 
shown to increase the transverse relaxivity of the na-
noprobe to over 400 Fe mM-1 s-1 at 7T [22-24].This in-
crease  in  T2  relaxivity  is  4  fold  higher  than  that  of 
Feridex®,  a  dextran-coated  SPIO  formulation  cur-
rently used in the clinics [25]. Integrin αvβ3 is an es-
tablished biomarker of angiogenesis, which is highly 
expressed  on  active  endothelial  cells  during  tumor 
angiogenesis, and has low to no expression in resting 
endothelium.  Using  nanoprobes  conjugated  with  a 
cyclic RGDfK (cRGD) peptide, an αvβ3-specific ligand, 
or a non-targeting cyclic RADfK (cRAD) control, we 
evaluated the change of MR signal intensity (SI) over 
time at different angiogenic “hot spots” in subcuta-
neous  tumor  xenografts  of  human  lung,  breast  and 
glioblastoma cancers. Comparison of the targeted and 
non-targeted SPPM data allows for the subtraction of 
signal intensity contributions from blood concentra-
tion, clearance and enhanced permeability and reten-
tion (EPR) effect. The net TR-MRI temporal profiles 
permit the assessment of the specific targeting kinetics 
of  cRGD-encoded  SPPM  to  αvβ3-expressing  tumor 
endothelial cells in vivo.  
MATERIALS AND METHODS 
Production of cRGD- and cRAD-SPPM. Meth-
oxy-  and  maleimide-terminated  poly(ethylene  gly-
col)-b-poly(D,L-lactide)  (MeO-PEG-PLA  and 
Mal-PEG-PLA),  tetramethylrhodamine  (TMR)- 
conjugated  MeO-PEG-PLA-TMR  copolymers  and 
SPIO nanoparticles were synthesized following pre-
viously published procedures [9, 14, 26, 27]. All co-
polymers had a molecular weight of 10 kD with 5 kD 
PEG and PLA blocks. The diameter of SPIO nanopar-
ticles was 9.0 ± 0.9 nm by transmission electron mi-
croscopy  (TEM,  JEOL  1200  EX  at  120  KeV). SPPMs 
were prepared by a solvent evaporation method [14]. 
Briefly,  a  mixture  of  MeO-PEG-PLA, 
MeO-PEG-PLA-TMR,  Mal-PEG-PLA  and  SPIO  in 
THF  was  added  dropwise  to  0.05  M  HEPES  buffer 
containing 0.01 M EDTA (pH 7.4) under sonication. 
The micelle suspension was then equally divided into 
two parts, and then shaken on an orbital shaker for 4 
hrs to allow THF to evaporate. A solution of either 
thiol-terminated  cRGD  or  cRAD  was  added  to  the Theranostics 2011, 1 
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micelle  solution.  The  solutions  were  then  shaken 
overnight  for  conjugation  of  peptides  to  malei-
mide-terminated  micelles.  Thiol-terminated  cRGD 
and  cRAD  were  obtained  by  deprotections  of  thio-
acetate-protected  cRGDfK  and  cRADfK  (Peptides 
International,  Louisville,  KY),  followed  by  prepara-
tive HPLC purifications. All SPPM formulations were 
filtered through 1.0 µm nylon syringe filters and con-
centrated  using  centrifugal  filters  (100  kDa  cutoff, 
Millipore, Billerica, MA). 
Animal  tumor  models.  Animal  studies  were 
approved by the Institutional Animal Care and Use 
Committee at UT Southwestern Medical Center and 
carried  out  according  to  its  guidelines.  Female 
athymic nude mice (27-30g) were used. The subcuta-
neous tumor xenografts were formed from non-small 
cell A549 lung cancer, MDA-MB-231 breast cancer, or 
U87  glioblastoma  cell  lines.  For  each  tumor  model, 
cells  were  injected  subcutaneously  into  the  dorsal 
flank  of  the  mouse.  Five  million  A549,  five  million 
matrigel-supplemented (20%) MDA-MB-231, and one 
million U87 cells were injected in 100 µL of phosphate 
buffered  saline  (PBS)  to  start  tumor  inoculation  in 
their  respective  groups.  Tumors  were  allowed  to 
grow to 300-500 mm3 at which time they were ran-
domized  into  cRGD-  and  cRAD-SPPM  treatment 
groups (n = 3 each) for MR imaging. Statistical analy-
sis was calculated using the Student's two-tailed t test 
with  P values ≤  0.05  considered  statistically  signifi-
cant. 
MR imaging. MRI studies were conducted in a 
7T horizontal bore small animal MRI scanner (Varian 
Inc., Palo Alto, CA). All mice were anesthetized with 
1-2% isoflurane mixed with pure oxygen via a nose 
cone and were placed in a stretched supine position 
with a respiratory sensor. SPPM was administered via 
a tail vein catheter at a dose of 10 mg Fe/kg or 0.18 
mmol Fe/kg. The catheter was made in-house with a 
27G 0.5 inch butterfly needle with PE10 tubing (50 cm 
in  length)  to  allow  for  injection  during  the  TR-MR 
imaging acquisition. The average dead volume of the 
catheter was 100-125 µL. The total injected volume for 
these experiments ranged from 400-500 µL. 
 Axial  and  coronal  two-dimensional  (2D)  fast 
spin-echo  sequence  images  were  first  acquired  as 
scout imaging to ensure the imaging position of the 
implanted  tumor.  The  imaging  parameters  were: 
TR/TE =1000/5.3 ms, bandwidth = 100 kHz, FOV = 
35 x 35 mm, matrix size = 128 x 128, slice thickness = 1 
mm, 17 slices with no gap, and NEX = 1. The image 
slice with the maximal tumor cross-section was cho-
sen for subsequent TR-MRI studies.  
TR-MRI images were acquired at a single slice 
position using the T2*-weighted method with a tem-
poral resolution of 1.3 s over 30 mins. The other im-
aging parameters were: TR/TE = 10/3 ms, flip angle = 
45°, FOV = 35 x 35 mm, matrix size = 128 x 128, slice 
thickness = 1 mm, and NEX = 1. Thirty seconds after 
the initial start of the TR-MRI sequence, a SPPM bolus 
was administered manually over 30-45 s, after which 
the line was flushed with saline (total injection time 
about 75 s). The serial images, In, were normalized by 
dividing signal intensity (SI) of each image by an av-
eraged value from 5 consecutive pre-injection images 
collected within the first 15 s of the TR-MRI sequence 
(Figure  1).  Hot  spot  regions-of-interest  (ROIs)  were 
selected in tumor sections where SI changed greater 
than  20%  over  the  30  min  scan  time  compared  to 
pre-injection SI values. For targeting kinetic analysis, 
pre-injection images within the first 15 s were aver-
aged to calculate the initial SI(0). Post-injection images 
yielded SI(t) at any given time. The nanoprobe con-
centrations (CSPPM) were estimated using the follow-
ing equation: CSPPM  R2* = -ln[SI(t)/SI(0)]/TE [28]. 
Three ROIs from each tumor xenograft were analyzed 
and averaged. Three animals were used in each im-
aging subgroup. Images were analyzed using ImageJ 
software (National Institutes of Health, NIH).  
In  vivo  pharmacokinetic  and  TEM  studies  of 
SPPM.  Experiments  involving  radioactive  materials 
were approved by the Radiation Safety Committee at 
UT  Southwestern  Medical  Center.  Female  athymic 
nude mice with MDA-MB-231 tumors (same as those 
above) were used for all radioactive pharmacokinetic 
studies. 3H (or T)-labeled cRGD- and cRAD-encoded 
SPPMs  were  prepared  from  75% 
MeO-PEG-PLA-C(O)CT3  and  25%  MAL-PEG-PLA. 
For  the  longer  term  (i.e.  24  hrs)  pharmacokinetic 
studies, 3H-labeled SPPM solutions were injected via 
the tail vein (n=3 for each SPPM group). Blood was 
collected via ocular vein at 1 min, 1, 2 , 4 , 8 , 12, and 24 
hrs  after  the  injection.  Plasma  was  isolated  from 
whole  blood  by  centrifugation  at  1000  rpm  for  10 
mins.  The  plasma  was  subsequently  mixed  with  a 
tissue solubilizer solution (1 mL, BTS-450, Beckman, 
CA)  at  room  temperature  for  5  hrs  followed  by  an 
addition  of  a  liquid  scintillation  cocktail  (10  mL, 
Ready Organic™, Beckman, CA) for 12 hrs. Amount 
of radioactive isotope was measured by a liquid scin-
tillation counter (Beckman LS 6000 IC).  
For the short term pharmacokinetic studies, 20 
µL plasma samples from the mouse were obtained at 
1, 10, 20, 40 and 60 mins after injection of cRGD-SPPM 
(10 mg Fe/kg) (n=4). Samples were digested in con-
centrated HCl overnight and analyzed for Fe content 
using atomic absorption spectroscopy (Varian Spec-
trAA 50, Varian) using Fe standards as a calibration 
curve.  Plasma  samples  for  TEM  analyses  were  col-Theranostics 2011, 1 
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lected 40 mins post-injection and placed on the carbon 
grid, blotted and imaged at 120 keV. The negatively 
stained TEM samples were prepared with 2% phos-
photungstic acid (PTA) prior to analysis. 
Histological analysis. After MR imaging, mice 
were injected with Hoechst 33342 (10 mg/kg) via the 
tail vein. The dye was allowed to circulate for 1 mi-
nute. The tumor tissue was resected and embedded in 
optimal cutting temperature medium and flash fro-
zen. Tissue sections were collected at 8 µm thickness 
on a Leica cryostat (model 3050S) and then fixed with 
-20 °C acetone, mounted and coverslipped. Fluores-
cence  micrographs  were  taken  on  an  upright  Leica 
microscope  (model  5500DM)  with  proper  excitation 
and  emission  filters  for  tetramethylrhodamine  dye 
(ex = 515-560 nm, em = 580-610 nm) and Hoechst (ex 
= 340-380 nm, em = 450-490 nm). 
RESULTS 
SPPM  characterization.  Spherical  SPPM  nano-
probes encoded with cRGD or cRAD peptides were 
produced  and  characterized  according  to  published 
procedures (Fig. 1A; ref. [9]). Nanoprobes had a size 
distribution of 57±12 and 53±10 nm for cRGD- and 
cRAD-SPPM, respectively by dynamic light scattering 
analysis  (data  not  shown).  All  cRGD-  and 
cRAD-SPPM  formulations  had  a  mean  transverse 
relaxivity of 406.6 ± 9.1 Fe mM-1s-1 at 7 T and less than 
10% difference in fluorescence emission properties.  
Representative in vivo TR-MRI data. Figure 1B 
illustrates  representative  dataset  in  mice  bearing 
subcutaneous A549 non-small cell lung tumor xeno-
grafts. The images are marked with color-coded re-
gions-of-interest  (ROIs)  that  correspond  to  the 
like-colored  signal  intensity  curves  with  the  tumor 
margins  outlined  in  yellow  (Fig.  1B,  lower  panel). 
Baseline images showed little to no SI difference in all 
tissues before injection. After injection (Fig. 1B, lower 
panel,  dashed  line),  major  blood  vessels  (systemic 
circulation)  showed  a  maximum  SI  loss  for  both 
cRGD- (Fig. 1B, green line) and cRAD-SPPM (Fig. 1B, 
purple line) treated mice. These vascular ROIs con-
tinued to show similar SI curves for the entire study, 
returning to ~ 40% normalized SI at 30 mins (Fig. 1B, 
lower panel right graph). An initial decrease of SI in 
tumor ROIs was observed in both cRGD- (Fig. 1B, red 
line)  and  cRAD-SPPM  (Fig.  1B,  blue  line)  treated 
animals. cRGD-SPPM tumor ROI showed decrease to 
40% SI and a sustained negative slope over the 30 min 
time span indicating more accumulation of SPPM in 
that ROI, i.e. tumor angiogenic endothelium, whereas 
the  cRAD-SPPM  tumor  ROI  showed  an  initial  de-
crease to 70% SI and then a positive slope towards 
returning to baseline. This could be due to the clear-
ance of the cRAD-SPPM particle from the blood and 
the tumor vasculature. Muscle tissues, as a reference, 
in cRGD- and cRAD-SPPM treated animals showed 
smaller  initial  deceases  in  SI  and  then  a  return  to 
baseline  over  the  30  min  imaging  period  (Fig.  1B, 
lower panel, brown and orange lines, respectively).  
Blood  clearance  half-lives  of  SPPM  by  3H 
polymer and Fe analyses. We modified the hydroxyl 
(-OH)  terminal  group  of  MeO-PEG-PLA  copolymer 
with  a  3H  radioactive  moiety  (-C(O)CT3)  for  the 
quantitative measurement of SPPM pharmacokinetics 
in  vivo.  Two  groups  of  animals  were  injected  with 
cRGD- and cRAD-encoded SPPM. Plasma clearance 
studies showed a two-phase behavior over 24 hrs (Fig. 
2A). The plasma half-lives (t1/2,α) for the α-phase were 
0.41±0.11  and  0.32±0.08  hrs  for  the  cRGD-  and 
cRAD-SPPM (n=3 for each SPPM formulation, mean ± 
s.d.),  respectively.  The  t1/2,β  values  for  the  β-phase 
were 2.26±0.32 and 3.85±0.50 hrs for the cRGD- and 
cRAD-SPPM (n=3), respectively (Fig. 2A). Pharmaco-
kinetic analysis of the Fe content in the plasma, using 
atomic  absorption  spectroscopy,  also  showed  the 
clearance of the SPPM from blood (Fig. 2B, black open 
circles).  Data  points  at  1  and  60  mins  from  the  3H 
polymer  pharmacokinetic  study  (Fig.2B,  red  open 
squares)  overlap  with  the  Fe  data  indicating  that 
SPPM nanoparticles were intact after dilution into the 
blood.  TEM  analysis  of  plasma  samples  showed 
spherical  clusters  of  SPIO  (Fig.  2C).  Moreover,  the 
core-shell architecture was maintained and elucidated 
in  the  2%  PTA  negatively  stained  TEM  sample 
showing SPIO encapsulation in the white hydropho-
bic core of the SPPM (Fig. 2C, right panel). Polymer 
and  Fe  pharmacokinetic  blood  clearance  data  and 
TEM  micrographs  corroborate  the  SI  data  from  the 
TR-MRI  studies,  and  indicate  that  the  SPPM  nano-
probe was still intact within 60 mins post-injection. At 
early  time  points,  differences  in  cRGD-SPPM  and 
cRAD-SPPM  blood  vessel  SI  curves  from  TR-MRI 
(Fig. 1B, lower panel, green and purple lines) are not 
statistically significant (e.g. P = 0.36 at 30 mins), which 
is  consistent  with  the  3H  polymer  pharmacokinetic 
data (Fig. 2A, green and purple lines) at 60 mins (P = 
0.15).  
Targeting  kinetics  of  αvβ3-specific  SPPM  in 
lung,  breast  and  brain  tumor  xenografts.  Further 
TR-MRI  studies  of  SPPM  in  multiple  subcutaneous 
tumor xenografts models were examined and quanti-
fied. SI values were converted to R2* values to reflect 
the non-linear relationship of MRI SI to SPPM  con-
centration. Tumor ROIs from human A549 lung can-
cer, MDA-MB-231 breast cancer and U87 glioblastoma 
cancer showed similar R2* profiles with cRGD-SPPM 
(black  lines  in  Fig.  3,  each  symbol  type,  i.e.  circle, Theranostics 2011, 1 
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square, triangle, represents the mean of 3 tumor ROIs 
from one animal) having a greater decrease in R2* 
compared to cRAD-SPPM (Fig. 3, gray lines). In dif-
ferent animal tumor models, cRGD-SPPM revealed a 
similar trend with a continuing decreasing R2* over 
the 30 min imaging time. cRAD-SPPM treated animals 
showed a returning trend to baseline or a sustained 
R2* (U87 model) over the 30 min imaging  acquisi-
tion.  To  assess  the  targeting  kinetics  of  the 
cRGD-SPPM to αvβ3-expressing tumor endothelium, a 
compartmental model was proposed to measure their 
accumulation kinetics (ka) (Fig. 4A).  
 
Figure 1. Schematic of superparamagnetic polymeric micelles (SPPM, A) and representative T2*-weighted images of tu-
mor-bearing mice (transverse image) after cRGD- or cRAD-SPPM injection (B, upper panel). ROIs are color coded with the 
temporal SI curves. Major blood vessels are green or purple, tumor ROIs are red or blue, with muscle brown or orange, for 
cRGD- and cRAD-SPPM treated animals, respectively. Tumor margins are outlined yellow. The corresponding signal in-
tensity curves show the varied temporal responses recorded by each ROI over a period of 30 mins (B, lower panel). The left 
graph showing the first 2 min of the study and the right graph showing 0-30 min of the same study. Vertical dashed lines 
indicate the start of the SPPM bolus (10 mg Fe/kg). Theranostics 2011, 1 
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Figure  2.  Measurement  of  the  pharmacokinetics  and 
structural integrity of SPPM nanoprobes. (A) Plasma con-
centration-time  relationships  (n=3  for  each  group)  for 
cRGD-SPPM  (green  line)  and  cRAD-SPPM  (purple  line) 
using 
3H-labeled  polymers  over  24  hrs.  (B)  Short-term 
plasma  concentration-time  relationships  measured  by  Fe 
content  (black  open  circles)  after  a  bolus  injection  of 
cRGD-SPPM (10 mg Fe/kg). Data from radiolabeled poly-
mers (1 min and 60 mins) are shown as red open squares. 
(C) TEM micrographs of plasma samples that were col-
lected 40 mins after bolus injection of cRGD-SPPM. The 
sample was negatively stained with 2% PTA solution (right 
micrograph). Scale bars = 100 nm. 
 
 
 
Figure 3. Mean R2* curves of tumor ROI from cRGD- 
(black symbols) and cRAD-SPPM (gray symbols) in mice 
bearing A549 (A), MDA-MB-231 (B) or U87 (C) subcuta-
neous xenografts (n=3 for each xenograft group). Squares, 
circles and triangles indicate the mean of three measured 
ROIs from one animal in each group. cRGD-SPPM tumor 
hot-spot ROIs (black symbols) show a continuous increase 
in the R2* over 30 mins, indicating SPPM accumulation in 
tumor  tissues.  In  comparison,  the  R2*  values  from 
cRAD-SPPM treated animals (gray symbols) show a main-
tained or trend toward baseline indicating clearance from 
the tumor tissue. 
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Figure 4. Scheme of the pharmacokinetic model (A) and experimental data (B-D) that describe the αvβ3-targeting kinetics 
of cRGD-SPPM in tumor-bearing mice. (A) Angiogenic endothelium compartment (black box) is proposed to model the 
accumulation rate (ka) of cRGD-SPPM. The tumor extravascular compartment (blue box) and blood compartment (red box) 
can  be  subtracted  from  cRAD-SPPM  control,  yielding  only  the  angiogenic  endothelium  compartment  for  analysis  of 
cRGD-SPPM nanoprobes. (B-D) cRGD-SPPM targeting kinetic curves in A549, MDA-MB-231 and U87 tumors, respectively. 
When fitted to a one-compartment pharmacokinetic model, cRGD-SPPM showed accumulation rates (ka) of 0.24 (R
2=0.51), 
0.22 (R
2=0.87) and 0.24 (R
2=0.83) min
-1 in A549, MDA-MB-231 and U87 tumors, respectively. The slopes of the linear fit (red 
lines) from data points after 10 mins also indicate a continuous but slower accumulation of the cRGD-SPPM, with slopes of 
0.19 (R
2=0.88), 0.18 (R
2=0.57) and 0.20 (R
2=0.90) min
-1 for A549, MDA-MB-231 and U87 tumors, respectively. 
 
 
 
Specifically,  the  targeting  kinetics  of  the 
cRGD-SPPM (Fig. 4A) was calculated by subtracting 
the mean cRGD-SPPM tumor ROI R2* curve (Fig. 3, 
black lines) from its corresponding cRAD-SPPM con-
trol  (Fig.  3,  gray  lines).  When  fitted  to  a  one  com-
partment model of distribution, cRGD-SPPM showed 
accumulation  rates  of  0.24  (R2=0.51),  0.22  (R2=0.87) 
and 0.24 (R2=0.83) min-1 in A549, MDA-MB-231 and 
U87 tumors, respectively (Fig. 4B-D). The data points 
after 10 mins also indicated a continuous accumula-
tion of the cRGD-SPPM in tumors, with slopes (linear 
regression) of 0.19 (R2=0.88), 0.18 (R2=0.57) and 0.20 
(R2=0.90)  min-1  for  A549,  MDA-MB-231  and  U87 
models, respectively (Fig. 4B-D, red lines). 
 
To  histologically  verify  that  the  R2*  in  the 
TR-MRI datasets were due to SPPM accumulation in 
the  tumor  tissue,  fluorescence  micrographs  of  the 
tumor ROIs were evaluated. By secondarily injecting 
Hoechst 33342 intravenously, nuclei of well-perfused 
vessels were identified (blue nuclei by white arrows, 
Fig.  5).  Red  fluorescence  was  observed  in  close 
proximity  to  these  vessels  in  cRGD-SPPM  treated 
mice (Fig. 5A), whereas a lesser and more diffusive 
punctate  pattern  was  found  in  the  cRAD-SPPM 
treated tumors (Fig.  5B). These data support previ-
ously published fluorescence and Prussian Blue his-
tological  data  that  show  cRGD-SPPM  nanoprobes 
specifically  targeting  αvβ3  on  angiogenic  vascular 
endothelium [9, 22]. Theranostics 2011, 1 
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Figure  5.  Fluorescence  micrographs  of  cryo-sectioned 
A549 tumor xenografts from cRGD- (A) and cRAD-SPPM 
(B) treated animals. Endothelial cells from highly perfused 
vessels (white arrows) are stained with Hoechst (blue). This 
staining is caused by the limited circulation time (1 min) of 
the Hoechst dye. cRGD-SPPMs are shown tightly associated 
with  these  vessels  (A,  red  fluorescence),  whereas 
cRAD-SPPMs are dispersed in a lesser content throughout 
the tumor parenchyma (B, red fluorescence). Scale bars = 
50 µm.  
 
DISCUSSION 
In molecular imaging studies, the surface of na-
noprobes  is  frequently  functionalized  with  tar-
get-specific  ligands  (e.g.  peptides,  mAbs,  etc),  and 
contrast  specificity  primarily  arises  from  the  differ-
ence in payload accumulation of targeted nanoparti-
cles  in  the  corresponding  cells  or  tissues  over  the 
non-targeted control. This strategy has resulted in the 
successful  imaging  of  multiple  cancer-specific  bi-
omarkers, such as αvβ3 and αvβ5 integrins, Her2-neu, 
transferrin and folate receptors  [9, 11-17]. However, 
several recent studies have raised serious questions 
on the efficacy of targeting ligands on the nanoparticle 
accumulation in tumor tissues. Multiple reports have 
shown that targeted nanoparticles did not lead to in-
creased  tumor  accumulation  over  the  non-targeted 
controls, although increased cellular uptake was ob-
served.  For  example,  Park  and  coworkers  reported 
that  liposomes  functionalized  with  anti-Her2  anti-
body did not result in significant difference in nano-
particle accumulation in subcutaneous BT474 breast 
xenografts over the stealth pegylated control over 170 
hrs [29]. Similar observations  were also reported in 
transferin- and folate receptor-targeted nanoparticles 
in different animal tumor models [16, 29]. More re-
cently, Nie and coworkers have shown that gold na-
norods that were functionalized with cRGD, EGFR- 
and  uPAR-ligands  did  not  lead  to  significantly  dif-
ferent uptake in A549 lung tumor xenografts over the 
non-targeted PEG-control 24 hrs after injection [30]. In 
contrary,  for  cRGD-encoded  nanoparticles,  tumor 
accumulation was found to decrease with the increase 
of cRGD density on the nanoparticle surface. Most of 
these studies attributed “passive” targeting from the 
EPR effect as the predominant mechanism of nano-
particle  accumulation  in  tumors.  Although  this 
mechanism  may  aid  in  the  overall  tumor  imaging 
effect,  it  is  detrimental  in  obtaining  targeted,  bi-
omarker-specific contrast in cancer molecular imaging 
applications. This is particularly important if the im-
aging goal is to monitor the dynamic expression of a 
disease biomarker (e.g. EGFR, v3) after chemother-
apy (e.g. Erbitux, Cilengitide) to assess the therapeutic 
efficacy. 
Due to the conflicting reports on the ligand effect 
on nanoparticle targeting specificity, more mechanis-
tic  studies  on  the  active  targeting  mechanism  are 
necessary. Most current imaging studies are carried 
out by comparing the pre- and post-contrast images of 
targeted  nanoparticles  over  non-targeted  control. 
These data provide only the “snap shot” information 
of targeting events at later time points. For many mo-
lecular  imaging  processes,  particularly  for  vascu-Theranostics 2011, 1 
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lar-targeted nanoparticles, the initial receptor binding 
and  nanoparticle  internalization  steps  may  occur  at 
much earlier times. Acquiring the early phase infor-
mation  on  nanoparticle  targeting  to  their  intended 
biomarkers  is  important  to  understand  the  in  vivo 
molecular recognition process for the rational design 
and  development  of  effective  molecular  imaging 
probes and their clinically translatable applications. 
This  study  proposes  a  time-resolved  MRI 
method for the non-invasive characterization of tar-
geted nanoprobes to their intended biological targets 
in vivo. Compared to nuclear imaging techniques (e.g. 
PET, SPECT), MRI has higher spatial resolution (<mm 
pixel size), which allows for the use of vascular “hot 
spots” to analyze the specific SPPM targeting kinetics. 
In a series of experiments, we measured the targeting 
kinetics of the cRGD-SPPM nanoprobes to αvβ3 integ-
rins  in  three  tumor  xenograft  models  in vivo  using 
single slice T2*-weighted TR-MRI. The high temporal 
resolution of this study (1.3s) has not been attempted 
before with targeted SPIO-based nanoprobes. Similar 
accumulation rates (ka) were found in the initial phase 
(<5 mins) across all three subcutaneous tumor types, 
and  furthermore,  a  sustained  accumulation  of 
cRGD-SPPM over 30 mins was also observed.  
SPPM nanoprobes used in this study are 50-75 
nm  in  diameter  with  estimated  molar  mass  around 
107-108 Da. Compared to small molecular agents (<1 
kD), nanoparticulates such as SPPM are limited in the 
diffusion, extravasation and penetration from blood 
vessels  into  tumor  tissues,  and  are  therefore,  well 
suited  to  target  angiogenic  endothelium  compart-
ments.  Although  the  current  TR-MRI  pharmacoki-
netic model was not as elaborate as conventional T1 
DCE-MRI models, the dynamic contrast profiles allow 
for  direct  comparisons  of  targeted  versus 
non-targeted T2 contrast agents.  
Results from this study showed that αvβ3 target-
ing kinetics by cRGD-SPPM had a significantly dif-
ferent  profile  from  the  non-targeted  cRAD-SPPM 
control in all three different tumor models. A contin-
uous  accumulation  of  the  cRGD-SPPM  (i.e.  SI  de-
crease) was observed over the 30 min time span (Fig. 
1B). The cRAD-SPPM profiles, however, showed an 
initial decrease in SI and then clearance from the tu-
mor ROI that matched the slope of the systemic blood 
vessel  ROI (Fig.  1B, lower panel, purple and blue), 
indicating  the  wash-out  of  the  non-targeted  SPPM 
from the tumor tissue. Control ROIs from muscle tis-
sues showed a slight decrease in SI that returned to 
baseline after 7-9 mins, which indicates that the per-
fusion of normal tissue does not cause similar kinetic 
profiles as observed in the cRGD- and cRAD-SPPM 
treated tumor tissue.  
To quantify the targeting kinetics of cRGD-SPPM 
to αvβ3 integrins in vivo, we subtracted the R2* curve 
of the non-targeted cRAD-SPPM control from that of 
cRGD-SPPM.  By  subtracting  the  non-targeted  R2* 
data,  we  hypothesized  that  blood  clearance,  extra-
vascular-extracellular components and other passive 
accumulation  mechanisms  (e.g.  EPR  effect)  are  ex-
cluded  (Fig.  4A).  The  use  of  a  single  compartment 
pharmacokinetic  model  revealed  similar  accumula-
tion  kinetics  between  the  tumor  models  with 
first-order rate constants of 0.24, 0.22 and 0.24 min-1 in 
A549,  MDA-MB-231  and  U87  tumors,  respectively. 
Although  U87  cells  are  also  known  to  express  αvβ3 
integrins [31, 32], the similar kinetic data suggest that 
only vascular targeting events were observed in U87 
tumors. This is likely due to the short time frame (<30 
mins)  of  TR-MRI  studies,  where  limited  nanoprobe 
extravasation from tumor vasculature is expected. It is 
further supported by the fact that the angiogenic en-
dothelial cells in tumor xenografts are mouse endo-
thelial cells in origin (i.e. independent of the injected 
human cancer cells), which may share similar expres-
sion  levels  of  αvβ3  integrins.  In  addition  to  single 
compartment analysis, we also performed linear re-
gression  analysis  at  later  times  between  10  and  30 
mins.  Data  show  an  increasing  trend  in  the 
cRGD-SPPM targeting kinetic profile (Fig. 4B-D, red 
lines),  indicating  a  continuous,  albeit  slower, 
cRGD-SPPM uptake in tumor endothelial cells. This 
two-phase behavior may explain the fast binding and 
uptake of the cRGD-SPPM during the initial contact 
with angiogenic endothelium, followed by the slower 
steady-state  kinetics  as  controlled  by  αvβ3  recycling 
and subsequent αvβ3-mediated endocytosis.  
These  data  clearly  demonstrate  that  increased 
tumor  accumulation  of  cRGD-encoded  SPPM  was 
observed at the vascular “hot spots” in tumors in the 
first 30 mins after SPPM injection. This is further cor-
roborated  by  3H-labeled  SPPM  studies,  where  a 
two-fold  increase  of  nanoparticle  accumulation  was 
observed  for  cRGD-encoded  SPPM  over  the 
non-targeted  control  60  mins  post-injection  [9].  Alt-
hough these data may appear to contradict with those 
reported  by  Nie  and  coworkers  [30],  it  should  be 
noted that the two studies were carried out at com-
pletely different time scales. In Nie’s study, the na-
noparticle  accumulation  was  examined  24  hrs  after 
nanoparticle injection. It is entirely feasible that longer 
interval  times  (i.e.  24  hrs)  will  favor  non-targeted 
PEG-particles (with longer blood circulation times) to 
“passively”  accumulate  in  the  tumor  parenchyma, 
despite clear advantages of targeted nanoparticles at 
the earliest stage of tissue targeting in vivo. For mo-
lecular imaging applications of vascular biomarkers, it Theranostics 2011, 1 
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will be advantageous to image as early as possible to 
obtain target-specific information. However, this will 
be limited by the prolonged circulation times of na-
noparticulates in blood, which will present significant 
background signals at early times. Therefore, one fu-
ture consideration for the target-specific nanoprobes 
should include an activatable design, where the im-
aging signals should be suppressed in blood but can 
be activated upon recognizing a specific biomarker of 
interest. This is currently under investigation in our 
lab. 
Several  considerations  are  warranted  from  the 
current  study.  First,  a  single  slice  MR  acquisition 
method was employed to ensure fast temporal reso-
lution (1.3 s). Multi-slice images using the same MRI 
parameters are possible to provide a more global un-
derstanding  of  SPPM  targeting  kinetics,  tumor  dis-
tribution and describing the heterogeneity of angio-
genic  tumor  endothelium[22].  For  this  purpose, 
however, a compromise in temporal resolution is an-
ticipated. It should also be noted that the current ki-
netic constants were obtained without the use of an 
arterial  input  function  or  blood  pool  data  in  our 
compartmental  analysis.  In  conventional  DCE-MRI, 
using the T1 agents, the blood pool data is critical in 
estimating  blood dynamic parameters such as  Ktrans 
and others. However, in our study the drastic loss of 
SI in the blood ROI kinetic curves exceeded the sensi-
tivity limit of the T2* acquisition, which prevents us 
from obtaining accurate estimation of the SPPM con-
centrations in the first minutes of analysis. Finally, a 
partial volume effect exists where the measured pixel 
(hotspot ROI) may contain a combined contribution 
from  both  tumor  parenchyma  and  vascular  com-
partments. In this study, we used the same ROI pixel 
size (4 x 4, or 1.1x1.1 mm) for the identified hot spot 
ROIs  for  cRGD-SPPM  and  cRAD-SPPM  groups.  By 
keeping the same pixel size, we consider that the par-
tial volume effect will have similar contributions to 
the  SIs  of  vascular  hot  spots  in  both  groups,  and 
therefore, won’t affect the relative kinetic analysis of 
the binding rates of cRGD-SPPM to αvβ3-expressing 
tumor  vasculatures.  Despite  these  complexities  and 
limitations that may affect the accuracy of the meas-
urement, the proposed study nevertheless provides a 
useful first attempt to quantitatively investigate the 
early phase of nanoparticle targeting to its intended 
molecular targets (i.e. v3) in the tumor vasculature 
in vivo. 
In summary, this study demonstrates the feasi-
bility to quantitatively measure the targeting kinetics 
of  cancer-specific  superparamagnetic  nanoprobes  to 
their  biological  targets  in  vivo.  In  particular, 
cRGD-SPPM targeting kinetics to αvβ3 integrins on the 
tumor endothelium was evaluated in tumor-bearing 
mice  using  the  T2*-weighted  TR-MRI  sequence. 
αvβ3-specific  accumulation  of  cRGD-SPPM  nano-
probes  in  tumor  vasculature  was  observed  at  early 
times with similar kinetic constants in three distinc-
tive  tumor  xenograft  models  (A549,  MDA-MB-231, 
and U87). These data indicate that broadened tumor 
specificity  can  be  achieved  in  targeting  angiogenic 
vasculature of tumors where vascular-targeted nano-
probes are less dependent on the specific tumor types. 
Furthermore, the data demonstrate for the first time 
that specific vascular targeting can be observed in as 
early as the first 10 mins post-injection of nanoprobes 
(although  not  surprisingly  due  to  the  direct 
blood-endothelium  contact).  These  results  provide 
useful  mechanistic  insights  for  the  development  of 
future  vascular-targeted  nanoprobes  to  capture  the 
early events of receptor targeting  kinetics (e.g. acti-
vatable nanoprobes). 
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